Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében [Diagnosis and treatment of polycythaemia vera state of the art] /
Polycythaemia vera (PV), a condition characterized by blood hyperviscosity due to the expansion of the erythrocyte mass is the most common entity among all Philadelphia chromosome-negative myeloproliferative neoplasms. Arterial and venous thrombotic events are leading determinants of morbidity and m...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2016
|
| Sorozat: | ORVOSI HETILAP
157 No. 44 |
| Tárgyszavak: | |
| doi: | 10.1556/650.2016.30583 |
| mtmt: | 3216670 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/24149 |
| LEADER | 01843nab a2200241 i 4500 | ||
|---|---|---|---|
| 001 | publ24149 | ||
| 005 | 20220420085820.0 | ||
| 008 | 220420s2016 hu o 0|| Magyar d | ||
| 022 | |a 0030-6002 | ||
| 024 | 7 | |a 10.1556/650.2016.30583 |2 doi | |
| 024 | 7 | |a 3216670 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Magyar | ||
| 100 | 1 | |a Marton Imelda | |
| 245 | 1 | 0 | |a Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében [Diagnosis and treatment of polycythaemia vera |h [elektronikus dokumentum] : |b state of the art] / |c Marton Imelda |
| 260 | |c 2016 | ||
| 300 | |a 1743-1751 | ||
| 490 | 0 | |a ORVOSI HETILAP |v 157 No. 44 | |
| 520 | 3 | |a Polycythaemia vera (PV), a condition characterized by blood hyperviscosity due to the expansion of the erythrocyte mass is the most common entity among all Philadelphia chromosome-negative myeloproliferative neoplasms. Arterial and venous thrombotic events are leading determinants of morbidity and mortality but impairment of quality of life due to vasomotor symptoms (erythromelalgia, pruritus) and disease-associated symptoms (tiredness, fatigue, pruritus, night sweats, vision problems, headache, concentration loss, abdominal discomfort, early satiety, fever, weight loss) are also present. The review of polycythaemia vera is actual as the updated WHO 2016 classification of myeloid neoplasms has changed the diagnostic criteria and a new second-line treatment option - JAK1/JAK2 inhibitor ruxolitinib - has been approved for patients who had an inadequate response to or are intolerant of hydroxyurea, which represents a breakthrough in the treatment of this patient population. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Simon Zsófia |e aut |
| 700 | 0 | 1 | |a Borbényi Zita |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/24149/1/MartonI.pdf |z Dokumentum-elérés |